Background In adults, intraventricular thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) facilitates resolution of intraventricular haemorrhage (IVH), reduces intracranial pressure, decreases duration of cerebrospinal fluid diversion, and may ameliorate direct neural injury. We hypothesize that patients with small parenchymal haematoma volumes (<30 cc) and relatively large IVH causing acute obstructive hydrocephalus would have improved clinical outcomes when given injections of low-dose rtPA to accelerate lysis and evacuation of IVH compared with placebo. Methods The Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage III trial is an investigatorinitiated, phase III, randomized, multicenter, double-blind, placebo-controlled study comparing the use of external ventricular drainage (EVD) combined with intraventricular injection of rtPA to EVD plus intraventricular injection of normal saline (placebo) for the treatment of IVH. Patients with known symptom onset within 24 h of the computed tomography scan confirmed IVH and third or fourth ventricle obstruction, with or without supratentorial intracerebral haemorrhage volume <30 cc, who require EVD are screened with a computed tomography scan at least six hours after EVD placement and, if necessary, at consecutive 12-h intervals until stabilization of any intracranial bleeding has been established. Patients who meet clinical and imaging criteria (no ongoing coagulopathy and no suspicion of aneurysm, arteriovenous malformation, or any other vascular anomaly) will be randomized to either intraventricular rtPA or placebo. Results The primary outcome measure is dichotomized modified Rankin Scale 0-3 vs. 4-6 at 180 days. Clinical secondary outcomes include additional modified Rankin Scale dichotomizations at 180 days (0-4 vs. 5-6), ordinal modified Rankin Scale (0-6), mortality and safety events at 30 days, mortality at 180 days, functional status measures, type and intensity of intensive care unit management, rate and extent of ventricular blood clot removal, and quality of life measures.
Introduction
Intraventricular haemorrhage (IVH) occurs in about 40% of primary intracerebral haemorrhage (ICH) and 15% of aneurysmal sub-arachnoid haemorrhage patients (1) (2) (3) . IVH is a significant and independent contributor to morbidity, and 30-day mortality is estimated at 40-80% (4, 5) . Recently, two large randomized controlled trials (RCTs) demonstrated the importance of IVH as a predictor of poor outcome. The Surgical Trial in ICH (STICH) enrolled 964 ICH patients, 42% of whom had intraventricular extension; of these, over half (55%) had obstructive hydrocephalus (6) . IVH with or without hydrocephalus was strongly associated with poor outcome; 31% without IVH and 15% with IVH experienced good outcome (P < 0·00001) (7) . When IVH and hydrocephalus were combined, good outcome rates fell to 11%. Similarly, IVH occurred in 49% of all patients enrolled in the NovoSeven ICH trial (n = 399). Modified Rankin scores at 3 months were consistently worse in this group of patients (8) . A prospective study of ICH patients indicates a direct, continuous relationship between the volume of IVH and mortality (9) . IVH contributes to morbidity by causing acute obstructive hydrocephalus, which elevates intracranial pressure (ICP) and decreases cerebral perfusion pressure, and, if severe enough, results in brain herniation. The current therapy for IVH with obstructive hydrocephalus is an external ventricular drainage (EVD). EVD alone is often an inadequate therapy and is complicated by catheter occlusion with blood clots (10) . EVD does not alter the rate of blood clot resolution (11) and therefore fails to decrease the degree and incidence of communicating hydrocephalus.
EVD lowers ICP, but controlling ICP does not usually result in immediate mental status improvement (12) . Thus, direct mass effect of IVH may be a significant pathophysiologic factor independent of ICP elevation. Persistent IVH is also associated with both mortality (12, 13) and decreased level of consciousness (14, 15) , which for poorly understood reasons, EVD does not consistently improve. Indeed, EVD may worsen edema and inflammation when complicated by bacterial meningitis. Other possible explanations include pro-inflammatory effects of the blood components (16) and permanent occlusion and scarring of arachnoid granulations where CSF is absorbed (17, 18) . The latter results in delayed communicating hydrocephalus, which necessitates permanent CSF shunt placement and is associated with impaired cognition, gait, balance, and urinary continence.
The natural history of IVH is for radiographically observed blood to gradually disappear over a period of two to four weeks, although remnants of IVH may persist for many months. Intraventricular thrombolysis facilitates blood clot removal and, in experimental studies, ameliorates prolonged inflammation and protects against delayed hydrocephalus (14, 19) . In a canine IVH model 20 000 IU of urokinase, administered every 12 h through an EVD until evidence of clot resolution, resulted in more rapid clearance of intraventricular blood (3-6 days vs. 38-65 days), more rapid return of consciousness (3 days vs. 7-9 days), lower incidence of delayed communicating hydrocephalus, and improved neurological outcome without increased injury to surrounding brain tissue (14, 19) compared with control animals. There were no intracranial or systemic haemorrhages, and no chronic changes in the brain or meninges on histology at three months in the treated group. In a pig model, Mayfrank et al. showed that the mass effect of clots distending the ventricle wall is the most important mechanism responsible for haemorrhagic ventricular dilatation and that this mass effect significantly diminished at the 1·5 h and seven-day time point when recombinant tissue plasminogen activator (rtPA) was used for intraventricular thrombolysis (20) . In both canine and porcine models, the greater the volume of blood clot injected into the ventricles the greater the likelihood of animal death.
Observational clinical studies and one small randomized trial have demonstrated improved clot resolution, ICP, ventricular size, and mortality with both intraventricular rtPA (off-label use) and urokinase (not currently available in the United States) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) . A Cochrane review of 10 independent studies (eight case series or retrospective studies, one quasi-randomized study, and one randomized study with a biased control group) using intraventricular thrombolytic agents found anecdotal evidence supporting safety and possible therapeutic value (34) . A more recent meta-analysis of 4 randomized and 10 observational studies found that intraventricular fibrinolysis was superior to EVD alone in terms of survival and short-term functional outcome (35) . Thus far, there are no randomized trials of sufficient size and quality to evaluate the safety and efficacy of this treatment modality.
The Intraventricular Hemorrhage Thrombolysis trial was a phase II, double-blind, randomized study that evaluated rtPA for clot lysis rate and safety. Forty-eight patients were randomized 1:1 to receive intraventricular injections of either 3·0 mg of rtPA (n = 26) or placebo (normal saline, n = 22) every 12 h until complete IVH resolution, EVD removal, or a safety end-point, whichever came first (36) . Frequency of death and ventriculitis was lower than expected, and bleeding events remained below the prespecified threshold: mortality (18% rtPA; 23% placebo), ventriculitis (8% rtPA; 9% placebo), and symptomatic bleeding (23% rtPA; 5% placebo; P = 0·1). The median duration of dosing was 7·5 days for rtPA and 12 days for placebo. There was a significant beneficial effect of rtPA on the rate of clot resolution (P < 0·001).
Dose interval finding studies [Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR) A and B] randomized patients 1:1 to receive intraventricular rtPA either at doses 0·3 or 1·0 mg q12h (n = 16) (CLEAR A) or to receive 1·0 mg q12h or q8h (n = 36) (CLEAR B). Direct measurement of the initial clot lysis rate (first three days of treatment) demonstrated dose-specific rates of 21·73%/day, 25·14%/day, 24·20%/day, and 19·98%/day for the 3·0 mg, 1·0 mg (q12h), 0·3 mg, and 1·0 mg (q8hr) groups, respectively. The safety profile for the two lower doses was numerically superior to the 3·0 mg dose with a symptomatic haemorrhage rate of 5·8% (3/52 patients).
Intraventricular thrombolysis is a rational therapy, with some data supporting its safety. At this point, however, there is insufficient evidence to recommend routine use in clinical practice. We have therefore designed a randomized controlled trial to test the hypothesis that intraventricular thrombolysis improves clinical outcomes in IVH patients.
Study objectives
The primary aim of this study is to test the hypothesis that IVH patients requiring EVD placement, with stabilized clots, will have better clinical outcomes when treated with intraventricular rtPA (1 mg q8h, up to 12 doses) relative to those receiving placebo within 72 h of onset.
Methods

Design
The CLEAR III study is a randomized, multicenter, doubleblinded, placebo-controlled phase III trial (two arms with 1:1 randomization for the first 104 patients followed by adaptive randomization) in ICH/IVH patients (Fig. 1 ). The protocol is registered with http://clinicaltrials.gov (NCT00784134) and approved by each site's Institutional Review Board.
Patient population -inclusion and exclusion criteria
Inclusion criteria
• Spontaneous ICH ≤30 cc and IVH obstructing third and/or fourth ventricles • Symptom onset less than 24 h prior to diagnostic CT scan • Age 18-80 years • An EVD must be in place and stable at the time of randomization, ideally using no more than two complete passes • Systolic blood pressure <200 mmHg sustained for the six hours before drug administration (closest to randomization)
• No test article may be administered until at least 12 h after symptom onset • Randomization within 72 h of CT scan diagnosing IVH, and • Modified Rankin Score (mRS) before ICH of 0 or 1.
Imaging inclusion criteria
• ICH/IVH clot stability: ICH must be ≤30 cc on initial presentation and not exceed 35 CT angiogram or digital subtraction angiogram with evaluation for 'spot sign' (37) is encouraged and considered standard of care to complete the evaluation for aneurysm, AVM, or other malformations. A copy of the diagnostic and stability CT electronic images is uploaded to the vision-edc (electronic data capture) online database prior to randomization (software pro-vided by Prelude Dynamics Inc., Austin, TX; study-specific implementation design developed by Emissary International LLC, Austin, TX). The Surgical and Reading Centers centrally review these scans to confirm eligibility and to measure ICH, IVH, and catheter tract clot volume/stability. All imaging data are electronically transferred and read at the Reading Center on a weekly basis to assure quality of CT-based decision making at the recruiting centers. After the last enrolled subject completes the one-year follow-up visit, data monitoring tasks will be completed to finalize and lock all clinical and radiological data. The co-ordinating center will remain blinded to follow-up clinical information and treatment designation until after data lock occurs.
Before dosing, the site investigator is required to view the most recent CT scan, confirming that the catheter tip is within the ventricular system. A CT scan is required daily on days one through five, and then repeated approximately 24 and 72 h post last dose of test article. During dosing, all patients must receive a minimum of one scan per day, or at least after every three doses. The CT scan will be evaluated by the site investigator for clot lysis and asymptomatic bleeding (including new onset or expansion of catheter tract haemorrhage) prior to the next administration of test article. An unscheduled CT scan will be done if the subject improves or worsens by more than two points on the Glasgow coma scale (GCS) motor score for greater than eight hours.
Randomization
Patients are randomized to receive the investigational product according to a centralized procedure co-ordinated via the online vision-edc system. The randomization system for investigational product is based on computer-generated randomization code lists, with stratification for thalamic and nonthalamic ICH location, and for IVH volume. The first 104 patients are randomized 1:1 to each treatment arm. Subsequently, the adaptive randomization scheme gives patients a weighted chance of being randomized to each treatment arm based upon the distribution of IVH size and ICH location of previously enrolled subjects at the time of the enrollment. Patients will be stratified for randomization by each of the following:
• ICH location (thalamic or nonthalamic), and • IVH volume (≤20, >20-≤50, or >50 ml) measured using planimetric techniques.
Treatment or intervention
A neurosurgeon and neurocritical care physicians or their trained designees perform EVD injections under standard sterile technique. Either 1·0 mg/1 ml of rtPA or one millilitre of normal saline is administered via the EVD. This is performed via isovolumetric injection to ensure clearance of the study drug from the catheter and delivery to the clot. At least five millilitres of CSF is removed prior to injection of one millilitre of test article, followed by a four millilitres flush of sterile saline into the ventricle. Injection is followed by closure of the catheter for one hour and then opening of the EVD for drainage of clot and CSF until the next injection every eight hours. The first EVD injection occurs after randomization, no sooner than 12 h after symptom onset. Treatment continues for up to 12 doses of test article unless the EVD is discontinued, an end-point of clot lysis is reached, or an adverse treatment end-point occurs (e.g. symptomatic haemorrhage). Treatment success end-points are (1) both third and fourth ventricles are open; (2) IVH-related mass effect (dilated or shifted ventricle) is resolved; or (3) an estimated 80% resolution of the IVH clot has occurred from the time clot stability was established. After the last dose, the EVD is closed for one hour and then reopened to drain for 24 h to allow for complete removal of test article and free plasmin. The EVD is removed when the patient tolerates 24 h of EVD closure, with no sustained elevation of ICP above 15 mmHg.
If the catheter does not remain patent, saline irrigation may be performed. Replacement of catheters is guided by neurosurgical clinical judgment. The Surgical Center located at the University of Chicago reviews all catheter placements and monitors clot removal assessments, catheter discontinuation protocols, and evaluates the safety and efficacy of the surgical procedure. None of these therapies are mandated in the protocol, but all are recorded in the case report form.
Supportive care includes ICP management with CSF drainage, as well as osmotic therapy, hyperventilation, analgesic sedation, induced coma, surgical management, and where indicated to control ICP.
Investigational medicinal product
The investigational product Alteplase (rtPA, Genentech, Inc., San Francisco, CA) is supplied as two milligrams lyophilized powder in glass vials. The dose of rtPA to be administered is 1·0 mg in one millilitre. Alteplase is reconstituted only with United States Pharmacopoeia-grade sterile water without preservatives for injection. The rtPA or normal saline (placebo) is prepared by the study pharmacist at each site and delivered to the intensive care unit (ICU) along with a four-milligram flush (nonbacteriostatic saline) in a separate packet.
Blinding
The investigational product and placebo appear identical and cannot be distinguished from each other. At the time of subject randomization, the EDC system transmits the treatment assignment via e-mail or fax to the unblinded site pharmacist and the central pharmacist. This is the only documentation of treatment assignment and is not viewable in the system by other study personnel. The unblinded pharmacist prepares the investigational product, which is clear and colorless, in the same manner as the placebo. All others involved in the conduct of the study are blinded to treatment allocation. The Data Safety Monitoring Board (DSMB) has access to pooled data and grouped by treatment assignment (A : B).
Primary outcomes
The primary outcome is the proportion of patients with mRS scores of 0-3 at day 180. 
Secondary outcomes
Data monitoring body
Safety interim analysis is undertaken when 100, 150, 250, and 400 patients have completed six-month assessments. These assessments will be conducted by an independent DSMB appointed by the National Institute of Neurological Disorders and Stroke (NINDS). Recruitment to the trial will be suspended if a threshold level is exceeded for the events of death prior to day 30 following symptom onset (40%), symptomatic rebleeding within 72 h of last dose (25%), and bacterial infection within 72 h of last dose (20%) for either treatment group. The DSMB may stop or recommend modification of the protocol at any point. No formal interim analyses for efficacy or futility are planned.
Prior to site activation and as needed, study personnel at each enrolling center are trained on the protocol, ICH Good Clinical Practices, investigator responsibilities, Food and Drug Administration requirements, surgical protocols, and EDC data entry screens to acquaint the center personnel with the design and methods of the trial, the study organization, treatment monitoring, and integrity of data collection. Remote monitoring of source documentation for every randomized subject serves to verify the accuracy and completeness of data in the vision-edc system, the existence of applicable regulatory files, and that the investigator's obligations are being fulfilled. Similar remote quality assurance methods are undertaken by the Surgical Center, the Outcomes Center, the Radiology Reading Center, the medical monitors, and the Safety Endpoint Committee to assure protocol compliance and data integrity.
Sample size
From the Safety, CLEAR IVH A, and CLEAR IVH B, studies we observed an absolute difference of 15-17% in the probability of better outcomes comparing EVD + rtPA with EVD + placebo with control rates around 25%. To determine a sample size that adequately powers the study, we performed Monte Carlo simulations. A variety of simulation scenarios were examined to judge the sensitivity of power toward sample size (n = 500, 600, and 700), effect size [odds ratio(OR) = 1·8 to 2·2], control group outcome rates (placebo rates of good outcome mRS ≤3 = 20%, 30%), model choice (correctly specified vs. noncorrectly specified model), and site clustering {between site heterogeneity parameterized as a latent effect with standard deviation 0·1 and 0·25 [i.e. 14%, 36% of log-odds ratio treatment effect = 0·7, (OR = 2·0), respectively]}. The total projected sample size of 500 participants randomized to receive either intraventricular rtPA or placebo (250 in each group) provides 80% or greater power to detect an absolute difference of 13% in the proportion of patients with mRS 0-≤3 outcome at six months (OR = 1·92, α = 0·05, twotailed comparison).
Statistical analyses
All randomized subjects will be included in randomized controlled trial (RCT) analyses on an intention-to-treat basis. Missing outcome data will be handled through multiple imputation procedures subject to the validity of missing-at-randomness assumptions. For the primary outcome analysis, the proportions of mRS 0-3 outcomes will be compared between treatment and placebo arms, adjusted for ICH location (thalamic and nonthalamic) and IVH volume, using a binary logistic regression model. Although both adjusted and unadjusted results will be reported, adjusted analysis is prespecified as the primary outcome analysis for this RCT.
A secondary analysis of the categorical shift in mRS will be undertaken on the full range (0-6) of the mRS using Cochran-Mantel-Haenszel shift test and proportional odds logistic regression subject to the validity of shift analysis model assumptions. Other secondary outcome analyses will be carried out according to standard statistical principles for comparison of parametric or nonparametric distributions as appropriate.
Study organization and funding
Both the steering committee and executive sub-committees manage this study. The study is financially supported by the National Institutes of Health (NIH)/Neurological and NINDS, grant-in-aid number 5U01NS062851. The study drug is provided by Genentech.
Conclusion
CLEAR III is the first, randomized, multicenter, double-blinded, placebo-controlled phase III trial assessing the efficacy of intraventricular thrombolytic therapy in IVH patients with an EVD. The allowance for dosing and EVD placement and removal decisions by nonstudy team physicians reflects the practical nature and generalizability of this study. If the study outcome is positive, it will significantly improve the therapeutic options for acute haemorrhagic stroke treatment. Based on available screening data, we estimate that 10-15% of all ICH, somewhere between 10 000 and 15 000 ICH subjects in the United States yearly, and 150-200 000 ICH subjects worldwide would be eligible for this therapy. It is an important step toward reducing the burden of ICH worldwide.
